Cargando…
Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors
In this work, design, synthesis, and screening of thiophene carboxamides 4–13 and 16–23 as dual vascular endothelial growth factor receptors (VEGFRs) and mitotic inhibitors was reported. All compounds were screened against two gastrointestinal solid cancer cells, HepG-2 and HCT-116 cell lines. The m...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136361/ https://www.ncbi.nlm.nih.gov/pubmed/30191744 http://dx.doi.org/10.1080/14756366.2018.1503654 |
_version_ | 1783354983883735040 |
---|---|
author | AbdElhameid, Mohammed K. Labib, Madlen B. Negmeldin, Ahmed T. Al-Shorbagy, Muhammad Mohammed, Manal R. |
author_facet | AbdElhameid, Mohammed K. Labib, Madlen B. Negmeldin, Ahmed T. Al-Shorbagy, Muhammad Mohammed, Manal R. |
author_sort | AbdElhameid, Mohammed K. |
collection | PubMed |
description | In this work, design, synthesis, and screening of thiophene carboxamides 4–13 and 16–23 as dual vascular endothelial growth factor receptors (VEGFRs) and mitotic inhibitors was reported. All compounds were screened against two gastrointestinal solid cancer cells, HepG-2 and HCT-116 cell lines. The most active cytotoxic derivatives 5 and 21 displayed 2.3- and 1.7-fold higher cytotoxicity than Sorafenib against HepG-2 cells. Cell cycle and apoptosis analyses for compounds 5 and 21 showed cells accumulation in the sub-G1 phase, and cell cycle arrest at G2/M phase. The apoptotic inducing activities of compounds 5 and 21were correlated to the elevation of p53, increase in Bax/Bcl-2 ratio, and increase in caspase-3/7.Compounds 5 and 21 showed potent inhibition againstVEGFR-2 (IC(50) = 0.59 and 1.29 μM) and β-tubulin polymerization (73% and 86% inhibition at their IC(50) values).Molecular docking was performed with VEGFR-2 and tubulin binding sites to explain the displayed inhibitory activities. |
format | Online Article Text |
id | pubmed-6136361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-61363612018-09-14 Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors AbdElhameid, Mohammed K. Labib, Madlen B. Negmeldin, Ahmed T. Al-Shorbagy, Muhammad Mohammed, Manal R. J Enzyme Inhib Med Chem Article In this work, design, synthesis, and screening of thiophene carboxamides 4–13 and 16–23 as dual vascular endothelial growth factor receptors (VEGFRs) and mitotic inhibitors was reported. All compounds were screened against two gastrointestinal solid cancer cells, HepG-2 and HCT-116 cell lines. The most active cytotoxic derivatives 5 and 21 displayed 2.3- and 1.7-fold higher cytotoxicity than Sorafenib against HepG-2 cells. Cell cycle and apoptosis analyses for compounds 5 and 21 showed cells accumulation in the sub-G1 phase, and cell cycle arrest at G2/M phase. The apoptotic inducing activities of compounds 5 and 21were correlated to the elevation of p53, increase in Bax/Bcl-2 ratio, and increase in caspase-3/7.Compounds 5 and 21 showed potent inhibition againstVEGFR-2 (IC(50) = 0.59 and 1.29 μM) and β-tubulin polymerization (73% and 86% inhibition at their IC(50) values).Molecular docking was performed with VEGFR-2 and tubulin binding sites to explain the displayed inhibitory activities. Taylor & Francis 2018-09-07 /pmc/articles/PMC6136361/ /pubmed/30191744 http://dx.doi.org/10.1080/14756366.2018.1503654 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article AbdElhameid, Mohammed K. Labib, Madlen B. Negmeldin, Ahmed T. Al-Shorbagy, Muhammad Mohammed, Manal R. Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors |
title | Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors |
title_full | Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors |
title_fullStr | Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors |
title_full_unstemmed | Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors |
title_short | Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors |
title_sort | design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas vegfr-2inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136361/ https://www.ncbi.nlm.nih.gov/pubmed/30191744 http://dx.doi.org/10.1080/14756366.2018.1503654 |
work_keys_str_mv | AT abdelhameidmohammedk designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors AT labibmadlenb designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors AT negmeldinahmedt designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors AT alshorbagymuhammad designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors AT mohammedmanalr designsynthesisandscreeningoforthoaminothiophenecarboxamidederivativesonhepatocellularcarcinomaasvegfr2inhibitors |